Targeted therapies in the treatment of gastric cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 224-235

  Ngeow, Joanne ^a   Tan, Iain Beehuat ^a   Choo, Su Pin ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Angiogenesis inhibitor; EGFR inhibitor; Gastric cancer; Targeted therapy

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MARIMASTAT; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; RALTITREXED; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APPLICATION SITE REACTION; BLEEDING; BREAST CANCER; CANCER CELL CULTURE; CANCER CONTROL; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MUSCULOSKELETAL DISEASE; MYELOMA; NEOVASCULARIZATION (PATHOLOGY); OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH TUMOR; THROMBOEMBOLISM; TUMOR GROWTH; TUMOR REGRESSION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 80052233331     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01407.x     Document Type: Review

References (91)

1. Devesa SS, Blot WJ, Fraumeni FJF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
2. Siewert J, Bottcher K, Stein H, Roder J. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer study. Ann Surg 1998; 228: 449-61.
3. Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9.
4. Webb A, Cunningham D, Scarffe JH etal. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7.
5. Vanhofer U, Rougier P, Wilke H etal. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57.
6. Pozzo C, Barone C, Szanto J etal. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15: 1773-81.
7. Bouche O, Raoul JL, Bonnetain F etal. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 2004; 22: 4319-28.
8. Roth AD, Maibach R, Falk S. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2004; 22 (Suppl.): 4020.
9. Van Cutsem E, Moiseyenko V, Tjulandin S etal. Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-7.
10. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: 1S-13S.
11. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Marinex L etal. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized histochemical detection system. Mod Pathol 2004; 17: 579-84.
12. Baselga J, Pfister D, Cooper MR etal. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-14.
13. Saltz LB, Meropol NJ, Loehrer PJ Sr etal. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
14. Saltz L, Rubin M, Hochster H etal. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (Abstr 7).
15. Cunningham D, Humblet Y, Siena S etal. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
16. Ciardiello F, Bianco R, Damiano V etal. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-16.
17. Prewett M, Hooper AT, Bassi R etal. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Cancer Res 2002; 8: 994-1003.
18. Woell E, Greil R, Eisterer W etal. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial of the Arbeitsgemeinschaft Medikamentoese Tumortherapie. J Clin Oncol 2009; 27: 4538-A.
19. Tebbutt N, Sourjina T, Strickland A etal. ATTAX2-docetaxel plus cetuximab as second line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multicenter phase II trial by the AGITG. Proc GI ASCO 2008; 26: 15554 (Abstr).
20. Pinto C, Di Fabio F, Siena S etal. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-7.
21. st line metastatic gastric cancer. Final results from a multicentre phase II study of the AIO upper GI group. J Clin Oncol 2007; 25 (18S): 4514 (Abstr).
22. Han SW, Oh DY, Im SA etal. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009; 100: 298-304.
23. Pinto C, Di Fabio F, Barone C etal. Cetuximab in combination with cisplatin and docetaxel as first line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2008; 26: 4575-A.
24. Zhang X, Xu J, Shen L etal. A phase II study of cetuximab with cisplatin and capecitabine as first line treatment in gastric cancer. Proc GI ASCO 2009; 73: LBA39 (Abstr).
25. Yeh K, Hsu C, Hsu C etal. Phase II study of cetuximab plus weekly cisplatin and 24 hour infusion of high dose 5 fluorouracil and leucovorin for the first line treatment of advanced gastric cancer. J Clin Oncol 2009; 27: 4567 (Abstr).
26. Rao S, Starling N, Cunningham D etal. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 21: 2213-19.
27. Merck KGaA. Erbitux in combination with xeloda and cisplatin in advanced esophago-gastric cancer (EXPAND) [updated 19 April 2011; cited 18 May 2011]. Available from.
28. Johannes Gutenberg University Mainz. Efficacy of cetuximab in combination with irinotecan and 5- FU/FA in treatment of metastatic gastric cancer (GC-CIF-2005) [updated 12 May 2010; cited 18 May 2011]. Available from.
29. Royal Marsden NHS Foundation Trust. REAL 3 Version 2.0: Trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer [updated 3 November 2009; cited 18 May 2011]. Available from.
30. Massachusetts General Hospital. Perioperative panitumumab and epirubicin, oxaliplatin and xeloda (EOX) in patients with gastroesophageal adenocarcinoma (EOXP) [updated 3 May 2010; cited 18 May 2011]. Available from.
31. Okines AF, Ashley S, Cunningham D etal. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010; 28: 3945-50.
32. Chinese Academy of Medical Sciences. Combination of nimotuzumab and concurrent radiotherapy and capecitabine for inoperable locally advanced or recurrent gastric cancer [updated 11 August, 2010; cited 18 May 2011]. Available from.
33. Doi T, Koizumi W, Siena S etal. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003; 22: 258 (Abstr 1036).
34. Rojo J, Tabernero E, Van Cutsem E etal. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD 1839). J Clin Oncol 2006; 24: 4309-11.
35. Ferry DR, Anderson M, Beddows K etal. Phase II trial of gefitinib (ZD 1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. Clin Cancer Res 2007; 13: 5869-71.
36. Tew WP, Shah M, Schwartz G etal. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Gastrointest Am Soc Clin Oncol Symp 2005; 85: A5 (Abstr 5).
37. Dragovich T, McCoy S, Urba SG etal. SWOG 0127: phase II trial of erlotinib in GEJ and gastric adenocarcinomas. J Clin Oncol 2006; 24: 4922.
38. Ciardiello F, Caputo R, Bianco R etal. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63.
39. Lammerts can Bueren JJ, Bleeker WK, Bogh HO etal. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006; 66: 7630-8.
40. Dassonville O, Bozec A, Fishcel JL etal. EGFR targeting therapies: monoclonal antibodies versus thyrosine kinase inhibitors. Crit Rev Oncol Hematol 2007; 62: 53-61.
41. Lordick F, Leon-Chong J, Kang Y etal. Her2 status of advanced gastric cancer is similar in Europe and Asia. Ann Oncol 2007; 18 (S7): 253 (Abstr).
42. Tanner M, Hollmen M, Junttila T etal. Amplification of Her-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2004; 16: 273-8.
43. Kim M, Jung E, Lee H etal. Evaluation of Her 2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization and real time, quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-93.
44. Grabash H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
45. Bang YJ, Van Cutsem E, Feyereislova A etal. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376: 687-97.
46. Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010; 376: 659-60.
47. Kim JW, Kim HP, Lm SA etal. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272: 296-306.
48. LaBonte M, Manegold P, Wilson P etal. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 2009; 125: 2957-69.
49. Wainberg Z, Anghel A, Desa AJ etal. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16: 1509-19.
50. Iqbal S, Goldman B, Lenz H, Fenoglio-Preiser C, Blanke C. A phase II SWOG study of GW572016 (lapatinib) as first-line therapy in patients (pts) with advanced or metastatic gastric cancer. 2007 ASCO Annual Meeting Proceedings Part I, Chicago. J Clin Oncol 2007; 25 (18 Suppl.): 4621.
51. Hecht JR, Urba SG, Koehler M etal. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. In: Gastrointestinal Cancers Symposium; 2008 [abst 43].
52. National Center for Tumor Diseases, Heidelberg. Lapatinib versus lapatinib with capecitabine as second-line treatment in her2-overexpressing metastatic gastro-esophageal cancer: a randomized phase II trial [updated 10 December 2010; cited 18 May 2011]. Available from.
53. Satoh T, Bang Y, Wang J etal. Interim safety analysis from TYTAN: a Phase III Asian Study of lapatinib in combination with paclitaxel as second line therapy in gastric cancer. J Clin Oncol 2010; 28: Abstr 4057.
54. laxoSmithKline. A phase III study for ErbB2 positive advanced or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib [updated 28 January 2011; cited 18 May 2011]. Available from.
55. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
56. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
57. Akagi M, Kawaguchi M, Liu W etal. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer. Br J Cancer 2003; 88: 796-82.
58. Shah M, Ramanathan R, Ilson D, Saltz L etal. A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesphageal (GEJ) adenocarcinoma. J Clin Oncol 2006; 24: 5201-6.
59. Kelsen D, Jhawer M, Ilson D etal. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: results of a Phase II clinical trial. J Clin Oncol 2009; 27: 4512-A.
60. Enzinger P, Ryan D, Regan E etal. Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008; 26: 4552Abstr.
61. El-Rayes B, Patel B, Zalupski M etal. A phase II study ofo bevacizumab, docetaxel and oxaliplatin in gastric and GEJ cancer. J Clin Oncol 2009; 27: 4563-A.
62. Enzinger P, Fidias B, Meyerhardt J etal. Phase II study of bevacizumab and docetaxel in metastatic esophageal an gastric cancer. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 2006; Abstract 68.
63. Kang Y, Ohtsu A, Van Cutsem E etal. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010; 28 (Suppl.): 18s (abstr LBA4007).
64. Bang Y, Kang Y, Kang W etal. Phase II study of sunitinib as second line treatment for advanced gastric cancer. Invest New Drugs 2010; [Epub].
65. Tokuyama J, Kubota T, Saikawa Y etal. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via supression of tumor angiogenesis. Anticancer Res 2005; 25: 17-22.
66. 1 monoclonal antibody targeting the vascular endothelial growth factor receptor. J Clin Oncol 2010; 28: 780-7.
67. Holash J, Davis S, Papdopoulos N etal. VEGF Trap: a VEGF blocker with potent anti tumor effects. Proc Natl Acad Sci U S A 2002; 99: 11393-8.
68. Konner J, Dupont J. Use of soluble recombinant decoy VEGF trap to inhibit VEGF activity. Clin Colorectal Cancer 2004; 4: S81-5.
69. Sun W, Powell ME, O'Dwyer P etal. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol 2008; 26: 4535.
70. Kordes U, Krappmann D, Heissmeyer V etal. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
71. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-50.
72. Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol 2003; 15: 347-52.
73. Brown K, Park S, Kanno T etal. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci U S A 1993; 90: 2532-6.
74. Shah MA, Power D, Kindler H etal. A multicenter, two-stage, phase II study of PS-341 in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Invest New Drugs DOI 10.1007/s10637-010-9474-7 Epub 25 June 2010.
75. Ocean AJ, Schnoll-Sussman F, Chen X etal. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Proc Gastrointest Am Soc Clin Oncol 2005; 98: (Abstr 31).
76. Ocean AJ, Lane ME, Xiang Z etal. Genetic analysis of proteasome-related pathways in advanced gastric adenocarcinomas (AGA) treated on a phase II study with the proteasome inhibitor, PS-341 (bortezomib) with or without irinotecan. Proc Gastrointest Am Soc Clin Oncol 2005; 117: (Abstr 69).
77. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
78. Nomura H, Sato H, Seiki M etal. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-6.
79. Honda M, Mori M, Ueo H etal. Matrix metalloproteinase-7 expression in gastric cancer. Gut 1996; 39: 444-8.
80. Sier CF, Kubben FJ, Ganesh S etal. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-7.
81. Monig SP, Baldus SE, Hennecken JK etal. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001; 39: 597-602.
82. Bramhall SR, Hallissey MT, Whiting J etal. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 1864-70.
83. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000: 19: 6642-50.
84. Lang S, Gaumann A, Koehl G etal. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007; 120: 1803-10.
85. Feng W, Brown R, Trung C etal. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK and NF kappa B pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 2008; 38: 195-209.
86. Hashimoo I, Koizumi K, Tatematsu M etal. Blocking on the CXCR4/mTOR signalling pathway induces the anti metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer 2008; 44: 1022-9.
87. Doi T, Muro K, Boku N etal. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010; 28: 1904-10.
88. Attard G, Fong PC, Molife R etal. Phase I trial involving the pharmacodynamic study of circulating tumor cells of CP751, 871©, a monoclonal antibody against the insulin-like growth factor 1 receptor with docetaxel in patients with advanced cancer. J Clin Oncol 2006; 24: 3023 (Abstr).
89. Bachleitner-Hoffmann T, Sun MY, Chen CT etal. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008; 7: 3499-508.
90. Nakajima M, Sawada H, Yamada Y etal. The prognostic significance of amplification and overexpression of c-MET and c-erb2 in human gastric carcinomas. Cancer 1999; 85: 1894-902.
91. Jhawer M, Kindler H, Wainberg Z etal. Assessment of two doping schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer: interim results of a multicenter phase II study. J Clin Oncol 2009; 27: 4502 (Abstr).